Physician profile
Paul E Brody
NPI 1548477029
$885.26
in general payments reported to CMS, 2019-2025
14 companies · $20.70 in 2025
The $20.70 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $212 · 2020: $111 · 2021: $76.86 · 2022: $147 · 2023: $171 · 2024: $147 · 2025: $20.70.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $323 · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $323.23 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $247.81 | 2019-2024 | |
| Genzyme Corporation | $125.00 | 2022 | |
| Strata Skin Sciences, INC. | $81.27 | 2020-2024 | Xtrac |
| Almirall LLC | $66.24 | 2019-2022 | |
| Amgen INC. | $56.32 | 2024 | Otezla |
| Biofrontera INC. | $55.91 | 2019 | |
| Arcutis Biotherapeutics, INC. | $48.80 | 2023 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $43.38 | 2019-2023 | Jublia |
| Abbvie INC. | $39.75 | 2019-2023 | Skyrizi |
| Regeneron Healthcare Solutions, INC. | $29.49 | 2020 | |
| Ucb, INC. | $27.27 | 2024 | Bimzelx |
| Celgene Corporation | $24.67 | 2019 | |
| Sun Pharmaceutical Industries INC. | $20.70 | 2025 | |
| Lilly USA, LLC | $18.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Brody listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.